Darzalex approved in EU to treat smoldering multiple myeloma
Johnson & Johnson‘s Darzalex (daratumumab) is now the first approved treatment for high-risk smoldering multiple myeloma (SMM) in the European Union (EU). SMM…
Marisa Wexler, MS, senior science writer—
Articles by Marisa Wexler
Scemblix now OK’d in Canada for treating newly diagnosed CML
More people in Canada with the rare blood cancer Ph+ CML — fully, Philadelphia chromosome-positive chronic myeloid leukemia — in the…
Early results ‘extremely positive’ for pancreatic cancer treatment combo
A clinical trial has revealed encouraging results for people with metastatic pancreatic cancer who received Ampligen (rintatolimod) alongside Imfinzi (durvalumab). Nearly two-thirds of…
Voranigo approval urged in EU for treatment of certain brain tumors
A committee of the European Medicines Agency (EMA) is recommending that the daily oral therapy Voranigo (vorasidenib) be approved in the European Union to treat…
Intervenn’s noninvasive ovarian cancer test to hit market this fall
A noninvasive diagnostic test to help distinguish ovarian cancer from benign pelvic masses will be available this fall. GlycoKnow Ovarian received a proprietary laboratory…
2 Blenrep combos for hard-to-treat myeloma approved for adults in EU
Two combination therapies using Blenrep (belantamab mafodotin) — designed to treat adults with relapsed or refractory multiple myeloma — have been approved in the…
Aucatzyl approved in Europe for relapsed/refractory B-ALL
The European Commission has approved Autolus Therapeutics’ cell therapy Aucatzyl (obecabtagene autoleucel) as a treatment for B-cell precursor acute lymphoblastic leukemia (B-ALL), an aggressive…
Verastem’s VS-7375 oral therapy on FDA fast track for pancreatic cancer
The experimental oral medication VS-7375 has been granted fast track designation for advanced pancreatic cancer in the U.S. The Food and Drug Administration (FDA)…
IGI, Abbvie team up to advance myeloma treatment ISB 2001
Ichnos Glenmark Innovation (IGI) is partnering with Abbvie to advance the development of ISB 2001, a multiple myeloma treatment candidate that’s now in…
AML treatment ICT01 granted FDA’s orphan drug status
ICT01, an immune-modulating therapy being developed by Imcheck Therapeutics for acute myeloid leukemia (AML), has been granted orphan drug status by the U.S. Food…
